AAPL 168.85 -0.1006% MSFT 392.79 -3.9774% GOOG 156.37 -2.9361% GOOGL 154.51 -2.9033% AMZN 170.725 -3.3213% NVDA 815.097 2.3002% META 431.97 -12.4681% TSLA 165.815 2.2729% TSM 133.785 0.6129% LLY 719.89 -1.6812% V 270.7 -1.5708% AVGO 1290.37 2.6694% JPM 193.02 -0.0311% UNH 494.02 1.379% NVO 124.29 -1.4822% WMT 60.13 0.4343% LVMUY 166.98 -2.7036% XOM 120.27 -0.6444% LVMHF 837.8671 -2.5453% MA 457.42 -1.0984%
Last update at 2024-04-25T14:55:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7346.00M | 6701.00M | 8133.00M | 9138.00M | 9545.00M |
| Minority interest | - | - | - | - | - |
| Net income | 6552.00M | 5893.00M | 7264.00M | 7842.00M | 8394.00M |
| Selling general administrative | 5414.00M | 5368.00M | 5730.00M | 5150.00M | 5332.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 19917.00M | 19525.00M | 19265.00M | 19006.00M | 19646.00M |
| Reconciled depreciation | 3417.00M | 3398.00M | 3601.00M | 2206.00M | 1946.00M |
| Ebit | 5335.00M | 6005.00M | 5794.00M | 9674.00M | 8991.00M |
| Ebitda | 8752.00M | 9403.00M | 9395.00M | 10427.00M | 10937.00M |
| Depreciation and amortization | 3417.00M | 3398.00M | 3601.00M | 753.00M | 1946.00M |
| Non operating income net other | -814.00000M | 259.00M | 256.00M | 753.00M | 674.00M |
| Operating income | 5335.00M | 6005.00M | 5794.00M | 9674.00M | 10263.00M |
| Other operating expenses | 16757.00M | 16835.00M | 16285.00M | 13688.00M | 13484.00M |
| Interest expense | 1406.00M | 1197.00M | 1262.00M | 1289.00M | 1392.00M |
| Tax provision | 794.00M | 808.00M | 869.00M | 1296.00M | 1151.00M |
| Interest income | - | - | 256.00M | 753.00M | 674.00M |
| Net interest income | -1406.00000M | -1197.00000M | -1006.00000M | -536.00000M | -718.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | 1505.00M | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 794.00M | 808.00M | 869.00M | 1296.00M | 1151.00M |
| Total revenue | 26323.00M | 25979.00M | 25424.00M | 23362.00M | 23747.00M |
| Total operating expenses | 10351.00M | 10381.00M | 10126.00M | 9332.00M | 9383.00M |
| Cost of revenue | 6406.00M | 6454.00M | 6159.00M | 4356.00M | 4101.00M |
| Total other income expense net | 2011.00M | 696.00M | 2339.00M | -536.00000M | -718.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 6552.00M | 5893.00M | 7264.00M | 7842.00M | 8394.00M |
| Net income applicable to common shares | 6552.00M | 5893.00M | 7264.00M | 7842.00M | 8394.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 65121.00M | 61165.00M | 62948.00M | 59707.00M | 66416.00M |
| Intangible assets | 16080.00M | 15182.00M | 16587.00M | 19413.00M | 7443.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2388.00M | 2367.00M | 2079.00M | 1888.00M | 1794.00M |
| Total liab | 61460.00M | 54465.00M | 53539.00M | 50034.00M | 53916.00M |
| Total stockholder equity | 3661.00M | 6700.00M | 9409.00M | 9673.00M | 12500.00M |
| Deferred long term liab | - | - | - | 606.00M | 864.00M |
| Other current liab | 12524.00M | 10731.00M | 10141.00M | 8511.00M | 7862.00M |
| Common stock | 32514.00M | 32096.00M | 31802.00M | 31531.00M | 31246.00M |
| Capital stock | 32514.00M | 32096.00M | 31802.00M | 31531.00M | 31246.00M |
| Retained earnings | -28622.00000M | -24600.00000M | -21408.00000M | -21330.00000M | -17977.00000M |
| Other liab | 7880.00M | 9059.00M | 8991.00M | 9861.00M | 10918.00M |
| Good will | 15529.00M | 14890.00M | 14689.00M | 14703.00M | 14699.00M |
| Other assets | 2158.00M | 6524.00M | 1258.00M | 955.00M | 1015.00M |
| Cash | 7629.00M | 7989.00M | 6266.00M | 6037.00M | 6945.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 15687.00M | 12184.00M | 11653.00M | 12835.00M | 13488.00M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 31316.00M | 25320.00M | 26720.00M | 23866.00M | 26984.00M |
| Short term debt | 1591.00M | 87.00M | 91.00M | 2953.00M | 4419.00M |
| Short long term debt | 1591.00M | 87.00M | 91.00M | 2953.00M | 4419.00M |
| Short long term debt total | 38945.00M | 33309.00M | 32986.00M | 29903.00M | 33929.00M |
| Other stockholder equity | 21709.00M | 18202.00M | -985.00000M | -528.00000M | -769.00000M |
| Property plant equipment | 5427.00M | 5184.00M | 4889.00M | 4928.00M | 4958.00M |
| Total current assets | 22186.00M | 19385.00M | 21144.00M | 18440.00M | 37618.00M |
| Long term investments | - | - | - | 799.00M | 683.00M |
| Net tangible assets | -27948.00000M | -23372.00000M | -21867.00000M | -24443.00000M | -9642.00000M |
| Short term investments | 1676.00M | 48.00M | 4381.00M | 2874.00M | 22359.00M |
| Net receivables | 5563.00M | 4895.00M | 4525.00M | 4057.00M | 3580.00M |
| Long term debt | 37354.00M | 33222.00M | 32895.00M | 26950.00M | 29510.00M |
| Inventory | 4930.00M | 4086.00M | 3893.00M | 3584.00M | 2940.00M |
| Accounts payable | 1572.00M | 1366.00M | 1421.00M | 1371.00M | 1207.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -231.00000M | -796.00000M | -985.00000M | -528.00000M | -769.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 32514.00M | 32096.00M | 31802.00M | 31531.00M | 31246.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -28622.00000M | -24600.00000M | -21408.00000M | -21330.00000M | -17977.00000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5899.00M | 6524.00M | 5639.00M | 2223.00M | 1698.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 42935.00M | 41780.00M | 41804.00M | 41267.00M | 28798.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 37354.00M | 33222.00M | 32895.00M | 26950.00M | 29510.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -6044.00000M | 733.00M | -4718.00000M | 19996.00M | 15027.00M |
| Change to liabilities | 268.00M | -567.00000M | 779.00M | -25.00000M | 710.00M |
| Total cashflows from investing activities | -6044.00000M | 733.00M | -5401.00000M | 5709.00M | 14339.00M |
| Net borrowings | 6622.00M | 795.00M | 2464.00M | -4514.00000M | -1121.00000M |
| Total cash from financing activities | -4037.00000M | -8271.00000M | -4867.00000M | -15767.00000M | -22490.00000M |
| Change to operating activities | 1019.00M | 119.00M | 1112.00M | 406.00M | 1249.00M |
| Net income | 6552.00M | 5893.00M | 7264.00M | 7842.00M | 8394.00M |
| Change in cash | -360.00000M | 1723.00M | 229.00M | -908.00000M | 3145.00M |
| Begin period cash flow | 7989.00M | 6266.00M | 6037.00M | 6945.00M | 3800.00M |
| End period cash flow | 7629.00M | 7989.00M | 6266.00M | 6037.00M | 6945.00M |
| Total cash from operating activities | 9721.00M | 9261.00M | 10497.00M | 9150.00M | 11296.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 3417.00M | 3398.00M | 3601.00M | 2206.00M | 1946.00M |
| Other cashflows from investing activities | -3721.00000M | 1613.00M | -75.00000M | -13669.00000M | 50.00M |
| Dividends paid | -4196.00000M | -4013.00000M | -3755.00000M | -3509.00000M | 3507.00M |
| Change to inventory | -742.00000M | -165.00000M | -215.00000M | -66.00000M | -3.00000M |
| Change to account receivables | -746.00000M | -429.00000M | -427.00000M | -504.00000M | -378.00000M |
| Sale purchase of stock | -6360.00000M | -4975.00000M | -3486.00000M | -7702.00000M | -17794.00000M |
| Other cashflows from financing activities | 6519.00M | -78.00000M | -90.00000M | -42.00000M | -68.00000M |
| Change to netincome | 485.00M | 3368.00M | -152.00000M | 205.00M | 334.00M |
| Capital expenditures | 936.00M | 880.00M | 608.00M | 618.00M | 738.00M |
| Change receivables | -746.00000M | -429.00000M | -427.00000M | -504.00000M | -378.00000M |
| Cash flows other operating | 487.00M | 1472.00M | -353.00000M | -136.00000M | 293.00M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -360.00000M | 1723.00M | 229.00M | -908.00000M | 3145.00M |
| Change in working capital | -733.00000M | -1194.00000M | -216.00000M | -731.00000M | 622.00M |
| Stock based compensation | 401.00M | 341.00M | 330.00M | 308.00M | 311.00M |
| Other non cash items | 1282.00M | 1276.00M | -195.00000M | -186.00000M | 386.00M |
| Free cash flow | 8785.00M | 8381.00M | 9889.00M | 8532.00M | 10558.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AMGN Amgen Inc |
-4.88 1.79% | 268.13 | 20.21 | 14.06 | 5.49 | 19.24 | 6.45 | 11.67 |
| LLY Eli Lilly and Company |
-12.31 1.68% | 719.89 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
-1.8 1.21% | 146.73 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-1.86 1.11% | 165.94 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| MRK Merck & Company Inc |
2.35 1.85% | 129.34 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert A. Bradway | Chairman, CEO & Pres | 1963 |
| Mr. Peter H. Griffith | Exec. VP & CFO | 1959 |
| Mr. Esteban Santos | Exec. VP of Operations | 1968 |
| Dr. David M. Reese M.D. | Exec. VP of R&D | 1963 |
| Mr. Murdo Gordon | Exec. VP of Global Commercial Operations | 1967 |
| Ms. Linda H. Louie | VP of Fin. & Chief Accounting Officer | NA |
| Mr. Mike Zahigian | Sr. VP & Chief Information Officer | NA |
| Mr. Arvind Sood | VP of Investor Relations | NA |
| Mr. Jonathan P. Graham | Exec. VP, Gen. Counsel & Sec. | 1961 |
| Ms. Nancy A. Grygiel | Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer | 1968 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...